| Joshua Shofner, | |
|
955 Main St Ste G6, Winchester, MA 01890-1992 | |
| (781) 729-4878 | |
| Not Available |
| Full Name | Joshua Shofner |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 17 Years |
| Location | 955 Main St Ste G6, Winchester, Massachusetts |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023218237 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 242212 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Winchester Hospital | Winchester, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Robert J Obrien Jr Md And Assoc Pc | 1557250586 | 6 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Center for Applied Medical Research at the same University of Navarra, as well as the Reina Sofía Hospital in Cordoba, Andalusia.
While attention remains focused on the number of COVID-19 deaths and new cases, a separate statistic - the number of recovered patients - may be equally important to the goal of minimizing the pandemic's infection rate as shelter-in-place orders are lifted.
ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.
› Verified 4 days ago
| Entity Name | Robert J Obrien Jr Md & Assoc Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588646715 PECOS PAC ID: 1557250586 Enrollment ID: O20040315001048 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Center for Applied Medical Research at the same University of Navarra, as well as the Reina Sofía Hospital in Cordoba, Andalusia.
While attention remains focused on the number of COVID-19 deaths and new cases, a separate statistic - the number of recovered patients - may be equally important to the goal of minimizing the pandemic's infection rate as shelter-in-place orders are lifted.
ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.
› Verified 4 days ago
| Entity Name | Leominster Dermatology Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710342878 PECOS PAC ID: 7416251483 Enrollment ID: O20160211001797 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Center for Applied Medical Research at the same University of Navarra, as well as the Reina Sofía Hospital in Cordoba, Andalusia.
While attention remains focused on the number of COVID-19 deaths and new cases, a separate statistic - the number of recovered patients - may be equally important to the goal of minimizing the pandemic's infection rate as shelter-in-place orders are lifted.
ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Shofner, 91 Munroe St, Apt 2r, Somerville, MA 02143-2023 Ph: () - | Joshua Shofner, 955 Main St Ste G6, Winchester, MA 01890-1992 Ph: (781) 729-4878 |
News Archive
As U.S. policymakers consider ways to ease prohibitions on marijuana, the public health approaches used to regulate alcohol and tobacco over the past century may provide valuable lessons, according to new RAND Corporation research.
The inactivity or "silence" of certain genes plays a fundamental role in the prognosis of acute lymphoblastic leukemia as well as in response to treatment, according to the results of research involving a team made up of specialists from the University Hospital of Navarra and the Center for Applied Medical Research at the same University of Navarra, as well as the Reina Sofía Hospital in Cordoba, Andalusia.
While attention remains focused on the number of COVID-19 deaths and new cases, a separate statistic - the number of recovered patients - may be equally important to the goal of minimizing the pandemic's infection rate as shelter-in-place orders are lifted.
ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.
› Verified 4 days ago
Robert J O'brien, Dermatology Medicare: May Accept Medicare Assignments Practice Location: 955 Main St, Suite G-6, Winchester, MA 01890 Phone: 781-729-4878 | |
Connor Joseph Comeau, Dermatology Medicare: Not Enrolled in Medicare Practice Location: 955 Main St, Winchester, MA 01890 Phone: 781-729-4878 | |
David Barzilai, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 955 Main St Ste G6, Winchester, MA 01890 Phone: 781-729-4878 Fax: 781-729-5989 | |
Dr. Suzanne Virnelli, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 955 Main St, Suite 108, Winchester, MA 01890 Phone: 781-729-4878 Fax: 781-729-5989 | |
Jane F Danahy, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 955 Main St, Suite 108, Winchester, MA 01890 Phone: 781-729-4878 | |
Marilyn R Capek, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 955 Main St, Suite # 308, Winchester, MA 01890 Phone: 781-729-3150 |